Role of anti-Siglec-15 in non-small cell lung cancer
Author:
Affiliation:

Baotou Central Hospital (the Baotou Affiliated Hospital of Inner Mongolia Medical University), Department of Cardiothoracic Surgery, Baotou 014000, China

Clc Number:

R-33

Fund Project:

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • |
  • Materials
  • |
  • Comments
    Abstract:

    As a newly discovered ICI, Siglec-15 is widely expressed in various tumor cell types, and PD-1/ PD-L1 expressions is mutually exclusive. Siglec-15 may be a new therapeutic target for PD-1/ PD-L1 as a treatment option for patients who do not respond to therapy. This review discusses the recent research of the characteristic pathways of Siglec- 15, its involvement in immune regulation mechanisms, and its tumor-related expression. Clinical application of an anti- Siglec-15 antibody was analyzed, and the therapeutic prospect of Siglec-15 for NSCLC treatment is discussed.

    Reference
    Related
    Cited by
Get Citation
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:June 21,2022
  • Revised:
  • Adopted:
  • Online: March 16,2023
  • Published: